These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 27409341)

  • 1. Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels.
    Beyrath J; Chekkat N; Smulski CR; Lombardo CM; Lechner MC; Seguin C; Decossas M; Spanedda MV; Frisch B; Guichard G; Fournel S
    Oncotarget; 2016 Oct; 7(40):64942-64956. PubMed ID: 27409341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Death receptor 5 is activated by fucosylation in colon cancer cells.
    Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
    FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
    Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
    Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.
    Lemke J; Noack A; Adam D; Tchikov V; Bertsch U; Röder C; Schütze S; Wajant H; Kalthoff H; Trauzold A
    J Mol Med (Berl); 2010 Jul; 88(7):729-40. PubMed ID: 20354842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.
    Cretney E; Takeda K; Smyth MJ
    Int J Biochem Cell Biol; 2007; 39(2):280-6. PubMed ID: 17097329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a novel anti-DR5 monoclonal antibody WD1 with the potential to induce tumor cell apoptosis.
    Wang J; Lin Z; Qiao CX; Lv M; Yu M; Xiao H; Wang Q; Wang L; Feng J; Shen B; Ma Y; Li Y
    Cell Mol Immunol; 2008 Feb; 5(1):55-60. PubMed ID: 18318995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
    van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
    BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An HPLC method associated with a thermodynamic analysis to compare the binding of TRAIL and its nanovectorized form to death receptors DR4 and DR5 and their relationship to cytotoxicity.
    Guillaume YC; Lethier L; André C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Nov; 1036-1037():142-148. PubMed ID: 27750195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.
    Gasparian ME; Bychkov ML; Yagolovich AV; Dolgikh DA; Kirpichnikov MP
    Biochemistry (Mosc); 2015 Aug; 80(8):1080-91. PubMed ID: 26547077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
    Milutinovic S; Kashyap AK; Yanagi T; Wimer C; Zhou S; O'Neil R; Kurtzman AL; Faynboym A; Xu L; Hannum CH; Diaz PW; Matsuzawa S; Horowitz M; Horowitz L; Bhatt RR; Reed JC
    Mol Cancer Ther; 2016 Jan; 15(1):114-24. PubMed ID: 26516157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation.
    Qiao C; Hu M; Guo L; Lv M; Lin Z; Geng J; Lang X; Li X; Li Y; Ma Y; Feng J; Shen B
    BMC Immunol; 2012 Jul; 13():40. PubMed ID: 22788777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.
    Tur V; van der Sloot AM; Reis CR; Szegezdi E; Cool RH; Samali A; Serrano L; Quax WJ
    J Biol Chem; 2008 Jul; 283(29):20560-8. PubMed ID: 18474604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.
    Bychkov ML; Gasparian ME; Dolgikh DA; Kirpichnikov MP
    PLoS One; 2014; 9(10):e109756. PubMed ID: 25310712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity.
    Pavet V; Beyrath J; Pardin C; Morizot A; Lechner MC; Briand JP; Wendland M; Maison W; Fournel S; Micheau O; Guichard G; Gronemeyer H
    Cancer Res; 2010 Feb; 70(3):1101-10. PubMed ID: 20103630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y; Zhang B
    Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The characteristic of an anti-human DR5 antibody A6.
    Wang YG; Zhao KP; Chen JG; Zhang JY; Yu M; Li Y; Shen BF
    Cell Mol Immunol; 2008 Jun; 5(3):183-8. PubMed ID: 18582399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tetravalent anti-DR5 antibody without cross-linking direct induces apoptosis of cancer cells.
    Liu F; Si Y; Liu G; Li S; Zhang J; Ma Y
    Biomed Pharmacother; 2015 Mar; 70():41-5. PubMed ID: 25776477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing TRAIL/TRAIL death receptor-based cancer therapies.
    Yuan X; Gajan A; Chu Q; Xiong H; Wu K; Wu GS
    Cancer Metastasis Rev; 2018 Dec; 37(4):733-748. PubMed ID: 29541897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Importin β1 Augments the Anticancer Effect of Agonistic Anti-Death Receptor 5 Antibody in TRAIL-resistant Tumor Cells.
    Kojima Y; Nishina T; Nakano H; Okumura K; Takeda K
    Mol Cancer Ther; 2020 May; 19(5):1123-1133. PubMed ID: 32156787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
    Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
    Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.